Taurochenodeoxycholic acid sodium salt

Product NameTaurochenodeoxycholic acid sodium salt
CAS6009-98-9
MFC26H45NO6S.Na
MW522.7
EINECS
MOL File6009-98-9.mol

Chemical Properties

Melting point	165-175 °C
storage temp.	room temp
solubility	Methanol (Slightly), Water (Slightly)
form	Solid
pka	<2
color	White to Off-White
BRN	3901205
Stability	Hygroscopic
InChIKey	IYPNVUSIMGAJFC-UKYQSIPTNA-M
SMILES	[Na].[S](=O)(=O)(O)CCNC(=O)CC[C@H]([C@@H]1[C@@]2([C@H]([C@H]3[C@@H]([C@@]4([C@H](C[C@H]3O)C[C@@H](CC4)O)C)CC2)CC1)C)C
CAS DataBase Reference	6009-98-9(CAS DataBase Reference)

Safety Information

Safety Statements	24/25
WGK Germany	3
F	3-10
HS Code	29309090
Storage Class	11 - Combustible Solids

MSDS

Provider	Language
SigmaAldrich	English

Usage And Synthesis

Description

Taurochenodeoxycholic acid (TCDCA) is a taurine-conjugated form of the primary bile acid chenodeoxycholic acid (CDCA; ). Serum levels of TCDCA increase approximately 5-fold in within two hours and begin to decrease within four hours during an oral lipid tolerance test in humans. Serum levels of TCDCA are increased in patients with liver cirrhosis and may serve as a marker of disease progression.

Chemical Properties

Solid

Uses

Labeled Taurochenodeoxycholic Acid, intended for use as an internal standard for the quantification of Taurochenodeoxycholic Acid by GC- or LC-mass spectrometry.

Uses

Taurochenodeoxycholic Acid Sodium Salt is a bile acid conjugate and metabolite Taurolithocholic Acid (T009100) with antiinflammatory activity. Taurochenodeoxycholic Acid has been shown to inhibit hepatocyte apoptosis through suppression of Bid translocation to mitochondria.

General Description

An ionic detergent used for solubilizing lipids and proteins.

in vivo

Taurochenodeoxycholic acid (12-Deoxycholyltaurine; TCDCA; 0.05, 0.1g/kg) sodium decreases the pulmonary coefficient in the model mice and reduces the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice and has no significant effects on MMP2^[2].
Taurochenodeoxycholic acid sodium significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation^[3].
Taurochenodeoxycholic acid sodium significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats^[4].

IC 50

Microbial Metabolite; Human Endogenous Metabolite

References

[1] HOFMANN A F. The continuing importance of bile acids in liver and intestinal disease.[J]. Archives of internal medicine, 1999, 159 22: 2647-2658. DOI: 10.1001/archinte.159.22.2647
[2] A. SCHMID. Bile Acid Metabolome after an Oral Lipid Tolerance Test by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)[J]. PLoS ONE, 2016, 11 1. DOI: 10.1371/journal.pone.0148869
[3] XIAONING WANG. Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis[J]. Journal of Proteome Research, 2015, 15 4: 1126-1134. DOI: 10.1021/acs.jproteome.5b00217

Taurochenodeoxycholic acid sodium salt

Chemical Properties

Safety Information

MSDS

Usage And Synthesis

Preparation Products And Raw materials

Taurochenodeoxycholic acid sodium salt Supplier

Taurochenodeoxycholic acid sodium salt manufacturers

Related Product Information